X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs FRESENIUS KABI ONCO. - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH FRESENIUS KABI ONCO. PANACEA BIOTECH/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 170.0 22.1 768.1% View Chart
P/BV x 3.8 3.1 121.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 PANACEA BIOTECH   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs149176 84.5%   
Low Rs8279 104.8%   
Sales per share (Unadj.) Rs84.137.7 223.3%  
Earnings per share (Unadj.) Rs-18.35.1 -359.4%  
Cash flow per share (Unadj.) Rs-6.76.7 -99.6%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.742.5 196.8%  
Shares outstanding (eoy) m61.25158.23 38.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.43.4 40.7%   
Avg P/E ratio x-6.325.0 -25.3%  
P/CF ratio (eoy) x-17.218.9 -91.1%  
Price / Book Value ratio x1.43.0 46.1%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,07420,135 35.1%   
No. of employees `0002.81.2 238.7%   
Total wages/salary Rs m1,449703 206.1%   
Avg. sales/employee Rs Th1,874.15,176.2 36.2%   
Avg. wages/employee Rs Th527.0610.4 86.3%   
Avg. net profit/employee Rs Th-407.7699.6 -58.3%   
INCOME DATA
Net Sales Rs m5,1545,963 86.4%  
Other income Rs m10018 554.4%   
Total revenues Rs m5,2545,981 87.8%   
Gross profit Rs m-7661,430 -53.6%  
Depreciation Rs m711258 275.7%   
Interest Rs m1,503-26 -5,780.8%   
Profit before tax Rs m-2,8811,216 -236.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,771-68 -2,600.4%   
Tax Rs m17342 4.9%   
Profit after tax Rs m-1,121806 -139.1%  
Gross profit margin %-14.924.0 -62.0%  
Effective tax rate %-0.628.1 -2.1%   
Net profit margin %-21.813.5 -161.0%  
BALANCE SHEET DATA
Current assets Rs m3,8105,102 74.7%   
Current liabilities Rs m8,3652,385 350.7%   
Net working cap to sales %-88.445.6 -194.0%  
Current ratio x0.52.1 21.3%  
Inventory Days Days156150 103.8%  
Debtors Days Days67113 59.3%  
Net fixed assets Rs m14,4805,148 281.3%   
Share capital Rs m61158 38.7%   
"Free" reserves Rs m9036,556 13.8%   
Net worth Rs m5,1276,732 76.2%   
Long term debt Rs m5,832952 612.4%   
Total assets Rs m19,43310,388 187.1%  
Interest coverage x-0.9-45.8 2.0%   
Debt to equity ratio x1.10.1 804.1%  
Sales to assets ratio x0.30.6 46.2%   
Return on assets %2.07.5 26.2%  
Return on equity %-21.912.0 -182.7%  
Return on capital %3.614.6 24.9%  
Exports to sales %24.574.5 32.9%   
Imports to sales %10.224.8 41.1%   
Exports (fob) Rs m1,2644,441 28.5%   
Imports (cif) Rs m5251,477 35.5%   
Fx inflow Rs m1,5395,298 29.1%   
Fx outflow Rs m9421,772 53.2%   
Net fx Rs m5973,525 16.9%   
CASH FLOW
From Operations Rs m5991,274 47.0%  
From Investments Rs m-438-1,204 36.4%  
From Financial Activity Rs m-303-196 154.3%  
Net Cashflow Rs m-141-126 111.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 0.6 0.3 200.0%  
FIIs % 1.3 9.6 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 9.1 259.3%  
Shareholders   10,259 42,599 24.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS